Now showing items 1-6 of 6
Metabolic and inhibitory differences between cytochromes P450 3A4 and 3A5
Cytochrome P450 (CYP) 3A4 and 3A5 constitute the dominant drug metabolizing enzymes in the liver and small intestine, and the content and activity of these enzymes is widely variable. Accurate knowledge of in vivo CYP3A activity is vital to predicting potential drug-drug interactions that may occur. Furthermore, any inhibitory ...
Blood safety and resource allocation: economic analyses of donated blood safety initiatives
Risk management at any cost has become the apparent policy of blood banks and regulators because of transfusion-transmitted HIV and hepatitis. However, blood bank opinion leaders suggest economic analyses of new interventions are increasingly important for choosing between competing interventions. In this document we explore ...
The economic and clinical outcomes and policy implications of gene expression profiling in breast cancer care
In the U.S., the majority of premenopausal breast cancer patients are recommended by clinical guidelines to receive adjuvant chemotherapy to prevent disease progression and increase survival. However, low-risk patients may be experiencing the side effects of chemotherapy, with no corresponding benefit, which may also lead to ...
The role of drug-lipid interactions in biodistribution and therapeutic effects for drugs incorporated into liposomes
While a number of drugs formulated in liposomes or lipid vesicles are approved for human use, many are formulated empirically, without a full or complete understanding the role of drug-lipid interactions. Hence, the primary goal of this thesis is to study the role of drug-lipid interactions in modulating biodistribution and ...